Pharmaceuticals · PH-08 · Quality control laboratory and data integrity
A result must not change. If it does, the change must leave a trace.
When moving to EU GMP, laboratory data integrity is examined separately. The state reimburses half of the certification-related consultancy costs, but the laboratory process remains the company's own responsibility.
Platform: Plant Pulse
Who it is for
- Head of QC
- Results.
- QA
- Batch release.
- IT
- System validation.
- Export
- Buyer requirements.
Where the problem lies
Results in Excel
Spreadsheets have no audit trail.
Instrument data
Results are transcribed manually from instruments.
Sample traceability
Samples are not linked to batches.
Deviations
Out-of-specification investigations are on paper.
How the loss is calculated
| Inspection observations | observations per inspection × corrective action cost per observation |
|---|---|
| Repeat testing | repeat tests per month × cost per test |
| Release delay | delay days per batch × delayed batches per month |
| Export | lost export market revenue per year |
Calculate with your data
Holding Cost of Batches Awaiting QC Release
This calculator estimates the monthly cost of finished batches waiting for QC laboratory results and the release decision.
Use spaces for thousands and a dot or comma for decimals. Use the same currency throughout.
Values stay in this page and are not sent to the server.
Scenario estimate
0 / 6 values entered
Enter your operating figures to see the estimate.
Results are estimates, not guaranteed savings. The target lead time is user-supplied and is not presented as attainable. This calculation does not confirm GMP/GDP compliance, inspection outcomes or validation status. Capital cost is based on batch cost, not selling price. Do not include capital cost in the storage cost input, or it will be double counted. Firm timelines and prices can only be assessed after an audit and based on measured data.
Formulas and assumptions
This calculator estimates the monthly cost of finished batches waiting for QC laboratory results and the release decision. It covers tied-up capital, based on batch cost, and quarantine storage cost. It compares your current release lead time with a target lead time that you define. The calculation period is one month. Retests, remediation of inspection findings, lost exports and lost sales are not included. Enter all values from your own site data.
- Average capital tied up awaiting release (current)
- Batches per month × 12 ÷ 365 days gives batches per day; this is multiplied by the current release lead time (days) and the cost per batch. The result is the average value of batches in quarantine at any time. It is stock value, not a cost.
- Monthly holding cost (current lead time)
- Batches per month × current lead time (days) × [cost per batch × annual rate % ÷ 100 ÷ 365 + daily storage cost per batch].
- Monthly holding cost (target lead time)
- Same calculation as for the current lead time, using your target lead time (days): batches per month × target days × [cost per batch × rate % ÷ 100 ÷ 365 + daily storage cost].
- Estimated monthly difference between current and target lead time
- Batches per month × (current − target lead time, days) × daily cost per batch. A negative result is shown as 0. This is an estimate, not guaranteed savings.
Facts and global practice
Presidential meeting
All 58 manufacturers hold national GMP and must align with EU GMP; products are exported to 55 countries.1
yuz.uz
From 1 June 2026, 50% of the cost of foreign consultancy services for EU GMP, US FDA GMP and WHO prequalification is reimbursed, capped at $50,000.2
anhor.uz
Only 12% of companies hold an international GMP certificate.3
No statistics were found on Uzbek inspections related to data integrity.
Sample, result and batch in one trail
The sample is linked to the batch, the result is entered from the instrument or via a form, every change is kept in the audit trail, and deviations are logged automatically.
- 01Sample
- Batch
- Time
- Location
- 02Test
- Instrument
- Result
- Specification
- 03Deviation
- OOS
- Investigation
- Decision
- 04Release
- QA
- Audit trail
- Archive
Modules
The current maturity level is shown next to each module.
| Sample and result log | With audit trail | Engineering capability |
|---|---|---|
| Deviation (OOS) log | Electronic | Engineering capability |
| Batch linkage (WMS) | Status | Commercially available |
| Full LIMS | Partner | In development |
How we start
- 01
Data integrity audit
Laboratory.
Outcome: Gaps.
- 02
Pilot
One test type.
Outcome: Audit trail.
- 03
Scale-up
All tests.
Outcome: Complete log.
- 04
Validation
With a partner.
Outcome: Inspection readiness.
What is measured
| Manual transcription | Share | Audit |
|---|---|---|
| OOS cases | Count | Log |
| Result turnaround time | Days | System |
| Audit trail completeness | % | System |
What is needed to start
- Head of QC
- List of tests
- List of instruments
- Validation requirements
What we do not promise
- Exact timeline and price without an audit
- GMP/GDP certification or inspection outcome
- Approving validation documents ourselves
- Unmeasured results
- Full LIMS (partner)
Self-check
- Are results stored in a system?
- Does every change leave a trace?
- Do instrument results arrive automatically?
- Are samples linked to batches?
- Is the OOS log electronic?
- Are user permissions restricted?
- Is the archive retention period defined?
- Has a reimbursement application been submitted?
- Has a consultant been selected?
- Is there a responsible person?
Laboratory audit
We review laboratory data integrity and identify inspection risks.
- Map of break points
- Pilot plan
- Implementation fee and monthly subscription
Other solutions in this industry
- PH-01GDP warehouse: temperature and batch data in one system
- PH-02Shelf life and FEFO
- PH-03Warehouse operations with marking codes
- PH-04Moving to EU GMP: the electronic batch record
- PH-05Plant warehouse: quarantine, release and raw materials
- PH-06Compliance with reference prices
- PH-07Reimbursement: prescription, code, receipt and ESF
- PH-09Imported medicines warehouse and customs requirements
- PH-10Packaging line productivity
Sources
- Presidential videoconference: expanding production in the pharmaceutical industry. president.uz, 05.03.2026.
- Decree of 05.03.2026 on incentives for the pharmaceutical sector: 2026 targets. yuz.uz, 2026.
- “12% of pharmaceutical companies in Uzbekistan meet international standards.” anhor.uz.